- PR Newswire•2 days ago
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in the peer-reviewed journal Breast Cancer Research and Treatment, reconfirming the value of the Oncotype DX Breast Recurrence Score® in guiding chemotherapy treatment decisions in certain node-positive patients. Consistent with previously published findings in Nature Partner Journals Breast Cancer, the new SEER Registries analysis demonstrates that breast cancer patients with limited node-positive disease who have low Breast Recurrence Score™ (RS) results have an excellent chance of breast cancer-specific survival (BCSS). These data, along with results from 14 additional Oncotype DX® studies in breast cancer patients, were also presented at the 15th St. Gallen International Breast Cancer Conference in Vienna.
- Zacks•4 days ago
On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.
- Zacks•4 days ago
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GHDX : Summary for Genomic Health, Inc. - Yahoo Finance
Genomic Health, Inc. (GHDX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Day's Range||31.04 - 31.85|
|52 Week Range||22.90 - 33.96|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-75.14|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|